Structure based design of novel irreversible FAAH inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 20, 2009, Pages 5970-5974

  Wang, Jane L ^a   Bowen, Scott J ^a   Schweitzer, Barbara A ^a   Madsen, Heather M ^a   McDonald, Joseph ^a   Pelc, Matthew J ^a   Tenbrink, Ruth E ^a   Beidler, David ^a   Thorarensen, Atli ^a  

^a PFIZER INC   (United States)

Author keywords

Endocannabinoid anandamide; FAAH; Fatty acid amide hydrolase; Inflammation; Irreversible FAAH inhibitors

Indexed keywords

AZETIDINE UREA; FATTY ACID AMIDASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; AZETIDINES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; PYRIDAZINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

RATTUS;

EID: 70349199021     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.101     Document Type: Article

References (19)

1. Lambert D.M., and Fowler C.J. J. Med. Chem. 48 (2005) 5059
2. Pacher P., Batkai S., and Kunos G. Pharmacol. Rev. 58 (2006) 389
3. Di Marzo V. Nat. Rev. Drug Disc. 7 (2008) 438
4. Ahn K., McKinney M.K., and Cravatt B.F. Chem. Rev. 108 (2008) 1687
5. Seierstad M., and Breitenbucher J.G. J. Med. Chem. 51 (2008) 7327
6. Boger D.L., Miyauchi H., Du W., Hardouin C., Fecik R.A., Cheng H., Hwang I., Hedrick M.P., Leung D., Acevedo O., Guimaraes C.R., Jorgensen W.L., and Cravatt B.F. J. Med. Chem. 48 (2005) 1849
7. Ahn K., Johnson D.S., Fitzgerald L.R., Liimatta M., Arendse A., Stevenson T., Lund E.T., Nugent R.A., Nomanbhoy T.K., Alexander J.P., and Cravatt B.F. Biochemistry 46 (2007) 13019
8. Mileni M., Johnson D.S., Wang Z., Everdeen D.S., Liimatta M., Pabst B., Bhattacharya K., Nugent R.A., Kamtekar S., Cravatt B.F., Ahn K., and Stevens R.C. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 12820
9. Ahn K., Johnson D.S., Mileni M., Beidler D., Long J.Z., McKinney M.K., Weerpana E., Sadagopan N., Liimatta M., Smith S.E., Lazerwith S., Stiff C., Kamtekar S., Bhattacharya K., Zhang Y., Swaney S., Becelaere K.V., Stevens R.C., and Cravatt B.F. Chem. Biol. 16 (2009) 411-420
10. Johnson D.S., Ahn K., Kesten S., Lazerwith S.E., Song Y., Morris M., Fay L., Gregory T., Stiff C., Dunbar J.B., Liimatta M., Beidler D., Smith S., Nomanbhoy T.K., and Cravatt B.F. Bioorg. Med. Chem. Lett. 19 (2009) 2865
11. Copeland R.A. Enzymes: A practical introduction to structure, mechanism, and data analysis. 2nd ed. (2000), Wiley-VCH, New York pp 318-349
12. Compound 2 was prepared from 3-hydroxy methylbenzoate in four steps.
13. Matassa, V. G. WO 9318029 A1, 1993.
14. Olefin separation condition: Set up AI 30×250 mm chiral column elute with 20% EtOH and 80% CO2. Sample dissolved in 20 mL EtOH, 25 mg/mL, 1 mL per inject. The olefin stereochemistry was assigned by 2D NMR.
15. Compound 10 was prepared as described in WO 08047229, 2008.
16. Corley E.G., Conrad K., Murry J.A., Savarin C., Holko J., and Boice G. J. Org. Chem. 69 (2004) 5120
17. Acharya H.P., and Kobayashi Y. Tetrahedron 62 (2006) 3329
18. Compound 16 was prepared through the similar sequence as compound 9.
19. The Pfizer Institutional Animal Care and Use Committee reviewed and approved the animal use in these studies. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.